Ralliant (NYSE:RAL) Upgraded to “Buy” at Wall Street Zen

Ralliant (NYSE:RAL) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Vertical Research downgraded shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research report on Wednesday, May 27th. Barclays increased their target price on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. TD Cowen lifted their price target on shares of Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Finally, Oppenheimer boosted their price target on Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Ralliant has a consensus rating of “Moderate Buy” and an average price target of $70.80.

Ralliant Stock Up 4.6%

Ralliant stock opened at $70.01 on Friday. The company has a market cap of $7.84 billion and a P/E ratio of -6.40. Ralliant has a 1-year low of $37.27 and a 1-year high of $75.41. The company has a fifty day simple moving average of $65.21 and a 200 day simple moving average of $53.13. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million for the quarter. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Research analysts anticipate that Ralliant will post 2.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ralliant

Several hedge funds and other institutional investors have recently made changes to their positions in RAL. Danske Bank A S acquired a new stake in shares of Ralliant during the 4th quarter worth approximately $25,000. V Square Quantitative Management LLC acquired a new position in Ralliant during the fourth quarter valued at approximately $26,000. Allworth Financial LP raised its position in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new stake in Ralliant during the third quarter worth $26,000. Finally, BOKF NA bought a new stake in Ralliant during the third quarter worth $29,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.